Edward Kerwin, MD
Allergy · Medford, ORNPI 1568465847
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (46.5%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 14 manufacturers reported payments, led by GSK at 36.1% of the total. Reporting peaked in 2019 at $29,573 and has fallen 99.8% since, to $52 in 2023.
Across 106 payments — averaging $624.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$24K
- AstraZeneca$12K
- Mylan Specialty L.p.$11K
- Boehringer Ingelheim$8K
- Astrazeneca UK Limited$4K
- Mylan Inc.$2K
- plus $5K from 8 others
Across 600 payments — averaging $11,488 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Romark Laboratories, LC$1.1M
- Amphastar Pharmaceuticals, Inc.$943K
- Teva Pharmaceuticals USA, Inc.$695K
- Cipla USA Inc.$523K
- Hikma Pharmaceuticals USA$430K
- AstraZeneca$364K
- plus $2.8M from 20 others
What the payments were for
- Consulting fees$30,78946%
- Speaking & faculty fees$19,51329%
- Grants$4501%
- Travel & lodging$12,29219%
- Food & beverage$3,1835%
- Education$90%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 19 | $23,886 |
| AstraZeneca | 18 | $12,128 |
| Mylan Specialty L.p. | 17 | $10,530 |
| Boehringer Ingelheim | 2 | $8,060 |
| Astrazeneca UK Limited | 25 | $4,110 |
| Mylan Inc. | 2 | $2,490 |
| Novartis | 10 | $2,233 |
| Pfizer | 3 | $1,612 |
| Merck | 5 | $922 |
| Teva Pharmaceuticals USA, Inc. | 1 | $146 |
| Blueprint Medicines Corporation | 1 | $52 |
| Regeneron Healthcare Solutions, Inc. | 1 | $26 |
| Grifols USA, LLC | 1 | $21 |
| Genentech USA, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Yupelri$10,321
- STIOLTO RESPIMAT$7,968
- NUCALA$7,800
- BREZTRI AEROSPHERE$6,000
- ANORO$5,200
- Wixela Inhub$2,490
- FASENRA$1,377
- BEVESPI AEROSPHERE$1,324
- MK-7264$793
- QBW251$680
- PROAIR$146
How this compares
Too few allergy providers in Oregonto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Breo ElliptaFluticasone/Vilanterol | 31 | $21,155 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 65 | $16,655 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 64 | $3,702 |
| Fluticasone Propionate | 60 | $984 |
| Montelukast Sodium | 49 | $947 |
| Triamcinolone Acetonide | 28 | $510 |
| Prednisone | 91 | $311 |
| Doxycycline Hyclate | 13 | $105 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKBreo Ellipta | $23,886 | $21,15531 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy providers in Oregonon file to place this against a meaningful peer group, so we don't.
Other allergy in Medford
- Kevin ParksMedford$37
- Alice ChouEugene$4K
- Candice RohrEugene$2K
- Laurel Anderson CowellPortland$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.